Physician profile
Eric Graves
NPI 1871574517
$1,345.95
in general payments reported to CMS, 2019-2025
19 companies · $330 in 2025
The $330 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47.49 · 2020: $98.70 · 2021: $253 · 2022: $211 · 2023: $187 · 2024: $219 · 2025: $330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $736.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $735.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $284.66 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $274.69 | 2020-2025 | |
| Glaxosmithkline, LLC. | $188.09 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $121.96 | 2020-2022 | |
| Abbott Laboratories | $92.31 | 2021-2022 | |
| Amgen INC. | $70.25 | 2020-2025 | Krystexxa, Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $39.06 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.98 | 2021-2023 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $35.42 | 2021-2022 | |
| Lilly USA, LLC | $34.15 | 2019-2023 | Mounjaro |
| Pfizer INC. | $30.94 | 2024-2025 | |
| Eisai INC. | $25.89 | 2021 | |
| Merck Sharp & Dohme LLC | $23.17 | 2021 | |
| Sanofi-Aventis U.S. LLC | $19.80 | 2022 | |
| Sanofi Pasteur INC. | $17.98 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $13.47 | 2020 | |
| Ibsa Pharma INC. | $12.20 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.11 | 2022 | |
| Allergan, INC. | $11.82 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Graves listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.